Search

An annual report from an influential cancer group highlights three MSK studies that have advanced cancer research.

… Wednesday, January 28, 2015 Summary An annual report from an influential cancer group highlights three MSK studies that have advanced cancer research. Memorial Sloan Kettering is pleased to share the news that the American Society of Clinical Oncology (ASCO) has recognized three of our recent studies

Researchers gain insight into leptomeningeal metastasis, a devastating complication of advanced cancer.

… Friday, July 17, 2020 Summary Cancer that has spread to the fluid and tissues of the brain and spinal cord, called leptomeningeal metastasis , is difficult to treat. It was not clear how the cancer cells survive in this space. A new discovery shows the cancer cells reprogram themselves to outcompete

Memorial Sloan Kettering Cancer Center (MSK) and Curadev Pharma, Inc., a biotechnology company developing novel immuno-oncology therapeutics, are expanding their collaboration through the MSK Therapeutics Accelerator program to advance the development of CRD3874-SI, Curadev’s first-in-class allosteric stimulator of interferon genes (STING) agonist for solid tumors.

… Friday, June 20, 2025 Memorial Sloan Kettering Cancer Center (MSK) and Curadev Pharma, Inc., a biotechnology company developing novel immuno-oncology therapeutics, are expanding their collaboration through the MSK Therapeutics Accelerator program to advance the development of CRD3874-SI, Curadev’s first-in-class

Minimally invasive techniques, improved postoperative care, and a multidisciplinary approach help make Memorial Sloan Kettering Cancer Center’s rates of esophageal surgical morbidity and mortality among the country’s lowest.

… Friday, September 23, 2016 At Memorial Sloan Kettering Cancer Center (MSK), we have made significant strides in the management of esophageal cancer over the past ten years. Improvements in postoperative care and the introduction of minimally invasive techniques have decreased the number of postoperative

MSK's Robert Motzer presented positive data from a phase III randomized study that assessed two different treatment combinations as first-line therapies that may benefit people with advanced kidney cancer.

… Monday, February 15, 2021 Update: On August 11, 2021, the FDA approved pembrolizumab (Keytruda®) plus lenvatinib (Lenvima®) for first-line treatments for patients with advanced renal cell carcinoma (RCC). Memorial Sloan Kettering Cancer Center (MSK) physicians and scientists presented new research at

Pediatric oncologists from around the world will gather in Lyon, France, from October 23 through 26, for the International Society of Paediatric Oncology’s annual meeting. Featuring new research and important discoveries — many led by MSK Kids researchers — the meeting will highlight the latest in the fields of pediatric oncology, including blood cancer, sarcoma, Wilms’ tumor, genomics, radiation oncology, and neuroblastoma.

… Tuesday, October 22, 2019 Pediatric oncologists from around the world will gather in Lyon, France, from October 23 through 26, for the International Society of Paediatric Oncology’s annual meeting. Featuring new research and important discoveries — many led by MSK Kids researchers — the meeting will

Positive results from a clinical trial published in The New England Journal of Medicine show that the combination of the immunotherapy drugs ipilimumab (Yervoy™) and nivolumab (Opdivo™), produced significantly better outcomes than ipilimumab alone in patients with advanced melanoma. A second piece in the same issue from MSK details a dramatic response occurring after a single dose of the combination therapy.

… Monday, April 20, 2015 Researchers from Memorial Sloan Kettering Cancer Center (MSK) are reporting exciting results in the field of cancer immunology. Positive results from a clinical trial published today in The New England Journal of Medicine show that the combination of the immunotherapy drugs ipilimumab

Diane Reidy-Lagunes sits down with Mary Elizabeth Williams to discuss what it was like being part of a phase 1 clinical trial, how clear communication can affect health outcomes, how guilt often accompanies survival, and what not to say to a cancer patient.

… Monday, November 29, 2021 When Mary Elizabeth Williams was diagnosed with stage 4 melanoma, she says: “My identity and my relationship with my mortality changed. That was the beginning of my new life.” Her decision to publicly disclose her diagnosis soon after receiving it was easy, she says. “I went

Data from 25,000 patients is helping scientists answer this and many other important questions.

… Thursday, February 3, 2022 Several years ago, in a lab meeting, one of Nikolaus Schultz’s postdoctoral fellows posed a question: “Do you think it’s possible to predict, based on the genomic profile of an individual tumor, which organs it might metastasize to?” And just like that, a research project was

Lonny Yarmus, DO, MBA, has been appointed Head of the Division of Subspecialty Medicine in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). A physician-scientist and internationally recognized leader in interventional pulmonology and procedural innovation, Dr. Yarmus is widely known for his expertise in minimally invasive diagnostics and therapeutics, outcomes research, and multidisciplinary program development.

… Tuesday, March 10, 2026 Lonny Yarmus, DO, MBA , has been appointed Head of the Division of Subspecialty Medicine in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). A physician-scientist and internationally recognized leader in interventional pulmonology and procedural innovation